This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Miranda H. Chakos, MD; Jose Ma. J. Alvir, DrPH; Margaret G. Woerner, PhD; Amy Koreen, MD; Stephen Geisler, MD; David Mayerhoff, MD; Steven Sobel, MD; John M. Kane, MD; Michael Borenstein, PhD; Jeffrey A. Lieberman, MD

Arch Gen Psychiatry. 1996;53(4):313-319.

Abstract
Background
There is controversy over whether tardive dyskinesia (TD) is solely a consequence of antipsychotic drug treatment or in part may reflect an intrinsic aspect of the disease process. Pathophysiologic factors could, independently or in concert with drug effects, lead to the development of dyskinetic signs.

Methods
We studied prospectively 118 patients in their first episode of psychosis who were treatment-naive or had less than 12 weeks of antipsychotic drug exposure at study entry. Patients received standardized antipsychotic drug treatment and were evaluated for up to 81/2 years with regular assessments of psychopathologic signs and symptoms and side effects.

Results
The cumulative incidence of presumptive TD was 6.3% after 1 year of follow-up, 11.5% after 2 years, 13.7% after 3 years, and 17.5% after 4 years. Persistent TD had a cumulative incidence of 4.8% after 1 year, 7.2% after 2 years, and 15.6% after 4 years. Taken individually, both antipsychotic drug dose, entered as a time-dependent covariate, and poor response to treatment of the first psychotic episode were significant predicters of time to TD. When antipsychotic drug dose and treatment response were examined together, treatment responders had significantly lower hazards for presumptive TD than nonresponders (hazard ratio, 0.29; 95% confidence interval, 0.09 to 0.97). Dose was a trend-level predicter, with each 100-mg chlorpromazine equivalent unit increase in dose associated with a 5% increase in the hazard of presumptive TD (hazard ratio, 1.05; 95% confidence interval, 0.99 to 1.11).

Conclusion
Poor response to the treatment of a first episode of psychosis and, to a lesser extent, antipsychotic drug dose are important factors in the development of TD. This suggests that there may be a disease-related vulnerability to TD manifest with antipsychotic drug exposure. Potential pathophysiologic factors might include neurodevelopmentally induced structural neuropathologic characteristics, sensitization of nigrostriatal dopamine neurons, and the induction of glutamatergically mediated neurotoxic effects.

Author Affiliations
From the Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY. Dr Lieberman is now with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study
Kelly et al.
J Psychopharmacol 2009;23:436-441.
ABSTRACT  

Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller et al.
Br. J. Psychiatry 2008;193:279-288.
ABSTRACT | FULL TEXT  

New-Onset Schizophrenia: Pharmacologic Treatment
Kane
Focus 2008;6:167-171.
ABSTRACT | FULL TEXT  

Drug-Induced Movement Disorders
Claxton et al.
Journal of Pharmacy Practice 2007;20:415-429.
ABSTRACT  

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck
Br. J. Psychiatry 2007;191:238-245.
ABSTRACT | FULL TEXT  

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Keefe et al.
Arch Gen Psychiatry 2007;64:633-647.
ABSTRACT | FULL TEXT  

Pharmacological Treatments for First-Episode Schizophrenia
Robinson et al.
Schizophr Bull 2005;31:705-722.
ABSTRACT | FULL TEXT  

Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness
Honer et al.
J Psychopharmacol 2005;19:277-285.
ABSTRACT  

Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients
STROUS and LERNER
Am. J. Psychiatry 2005;162:631-632.
FULL TEXT  

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos et al.
Focus 2004;2:111-121.
ABSTRACT | FULL TEXT  

Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol
Lieberman et al.
Am. J. Psychiatry 2003;160:1396-1404.
ABSTRACT | FULL TEXT  

Prevention of Relapse in Schizophrenia
Geddes
NEJM 2002;346:56-58.
FULL TEXT  

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos et al.
Am. J. Psychiatry 2001;158:518-526.
ABSTRACT | FULL TEXT  

Low dose typical antipsychotics - a brief evaluation
Taylor
Psychiatr. Bull. 2000;24:465-468.
FULL TEXT  

Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson et al.
Am. J. Psychiatry 1999;156:544-549.
ABSTRACT | FULL TEXT  

Spontaneous Abnormal Involuntary Movements in First-Episode Schizophrenia and Schizophreniform Disorder: Baseline Rate in a Group of Patients From an Irish Catchment Area
Gervin et al.
Am. J. Psychiatry 1998;155:1202-1206.
ABSTRACT | FULL TEXT  

Who Gets Tardive Dyskinesia?
JWatch Psychiatry 1996;1996:9-9.
FULL TEXT